Study S000907

Short-term Mazdutide Plus Lifestyle Intervention Versus Placebo for Pre-hepatectomy Prehabilitation in Living Liver Donors With MASLD: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

ClinicalTrials.gov record

Registration

Registration: NCT07718126
Acronym: PRIME
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 60
Start: 2026-09-01
Primary completion: 2029-02-28
Lead sponsor: West China Hospital
Conditions: Metabolic Dysfunction-Associated Steatohepatitis; Hepatic Steatosis; Living Liver Donors
Interventions: DRUG:Mazdutide; DRUG:Placebo (Normal Saline); BEHAVIORAL:Lifestyle Optimization
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Proportion of Participants Achieving Resolution of MASLD Without Worsening of Liver Fibrosis (ROM) [From randomization (Week 0) to Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.